SBT6050 combines pertuzumab as a HER2-directed monoclonal antibody with a selective small molecule toll-like receptor 8 (TLR8) agonist which aims to activate myeloid cells, including macrophages and dendritic cells (DCs), and NK and T cells in HER2-positive tumors including CRC. Here, ERBB2 is linked to colorectal carcinoma.